TY - JOUR
T1 - The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
AU - Faloppi, Luca
AU - Bianconi, Maristella
AU - Giampieri, Riccardo
AU - Sobrero, Alberto
AU - Labianca, Roberto
AU - Ferrari, Daris
AU - Barni, Sandro
AU - Aitini, Enrico
AU - Zaniboni, Alberto
AU - Boni, Corrado
AU - Caprioni, Francesco
AU - Mosconi, Stefania
AU - Fanello, Silvia
AU - Berardi, Rossana
AU - Bittoni, Alessandro
AU - Andrikou, Kalliopi
AU - Cinquini, Michela
AU - Torri, Valter
AU - Scartozzi, Mario
AU - Cascinu, Stefano
PY - 2015
Y1 - 2015
N2 - Although lactate dehydrogenase (LDH) serum levels, indirect markers of angiogenesis, are associated with a worse outcome in several tumours, their prognostic value is not defined in pancreatic cancer. Moreover, high levels are associated even with a lack of efficacy of tyrosine kinase inhibitors, contributing to explain negative results in clinical trials. We assessed the role of LDH in advanced pancreatic cancer receiving sorafenib. Seventy-one of 114 patients included in the randomised phase II trial MAPS (chemotherapy plus or not sorafenib) and with available serum LDH levels, were included in this analysis. Patients were categorized according to serum LDH levels (LDH ≤ vs. > upper normal rate). A significant difference was found in progression free survival (PFS) and in overall survival (OS) between patients with LDH values under or above the cut-off (PFS: 5.2 vs. 2.7 months, p = 0.0287; OS: 10.7 vs. 5.9 months, p = 0.0021). After stratification according to LDH serum levels and sorafenib treatment, patients with low LDH serum levels treated with sorafenib showed an advantage in PFS (p = 0.05) and OS (p = 0.0012). LDH appears to be a reliable parameter to assess the prognosis of advanced pancreatic cancer patients, and it may be a predictive parameter to select patients candidate to receive sorafenib.
AB - Although lactate dehydrogenase (LDH) serum levels, indirect markers of angiogenesis, are associated with a worse outcome in several tumours, their prognostic value is not defined in pancreatic cancer. Moreover, high levels are associated even with a lack of efficacy of tyrosine kinase inhibitors, contributing to explain negative results in clinical trials. We assessed the role of LDH in advanced pancreatic cancer receiving sorafenib. Seventy-one of 114 patients included in the randomised phase II trial MAPS (chemotherapy plus or not sorafenib) and with available serum LDH levels, were included in this analysis. Patients were categorized according to serum LDH levels (LDH ≤ vs. > upper normal rate). A significant difference was found in progression free survival (PFS) and in overall survival (OS) between patients with LDH values under or above the cut-off (PFS: 5.2 vs. 2.7 months, p = 0.0287; OS: 10.7 vs. 5.9 months, p = 0.0021). After stratification according to LDH serum levels and sorafenib treatment, patients with low LDH serum levels treated with sorafenib showed an advantage in PFS (p = 0.05) and OS (p = 0.0012). LDH appears to be a reliable parameter to assess the prognosis of advanced pancreatic cancer patients, and it may be a predictive parameter to select patients candidate to receive sorafenib.
KW - Angiogenesis
KW - Lactate dehydrogenase
KW - Pancreatic cancer
KW - Sorafenib
KW - TKI
UR - http://www.scopus.com/inward/record.url?scp=84946606628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946606628&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.5197
DO - 10.18632/oncotarget.5197
M3 - Article
AN - SCOPUS:84946606628
VL - 6
SP - 35087
EP - 35094
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 33
ER -